JP Morgan Maintains Overweight on Imax, Lowers Price Target to $47

Benzinga Newsdesk www.benzinga.com Negative 77.1%

Neg 77.1% Neu 0% Pos 0%

JP Morgan analyst David Karnovsky maintains Imax (NYSE:IMAX) with a Overweight and lowers the price target from $48 to $47.